Correction: Genetically enhanced T lymphocytes and the intensive care unit

Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian

doi:10.18632/oncotarget.25983

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Genetically enhanced T lymphocytes and the intensive care unit

PDF | How to cite

Oncotarget. 2018; 9:32097-32097. https://doi.org/10.18632/oncotarget.25983

Metrics: PDF 1841 views | ?

Tiberiu Tat^1,2, Huming Li³, Catalin-Sorin Constantinescu^1,4, Anca Onaciu⁵, Sergiu Chira⁵, Ciprian Osan⁵, Sergiu Pasca⁵, Bobe Petrushev⁵, Vlad Moisoiu⁵, Wilhelm- Thomas Micu⁵, Cristian Berce⁶, Sebastian Tranca², Delia Dima⁷, Ioana Berindan- Neagoe⁵, Jianliang Shen⁸, Ciprian Tomuleasa^7,9and Liren Qian⁸

¹ Intensive Care Unit, Ion Chiricuta Clinical Cancer Research, Cluj Napoca, Romania
² Department of Anesthesiology-Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
³ Department of Pulmonary and Critical Care Medicine, Navy General Hospital of PLA, Beijing, China
⁴ Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
⁵ Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
⁶ Department of Experimental Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
⁷ Department of Hematology, Ion Chiricuta Clinical Cancer Research, Cluj Napoca, Romania
⁸ Department of Hematology, Navy General Hospital of PLA, Beijing, China
⁹ Research Center for Functional Genomics and Translational Medicine / Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

Published: August 10, 2018

This article has been corrected: The correct Acknowledgment information is given below:

ACKNOWLEDGMENTS

Tiberiu Tat, Huming Li and Catalin Constantinescu contributed equally to the current paper. The research on CAR-T cells was funded by an internal grant of the Iuliu Hatieganu University, awarded to Tiberiu Tat, as well as by a National Grant of the Romanian Government, for postdoctoral research, awarded to Delia Dima. This paper was financed by a grant awarded to Ciprian Tomuleasa - FDI - 2018.

Original article: Oncotarget. 2018; 9:16557-16572. DOI: https://doi.org/10.18632/oncotarget.24637.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25983

Publication Alerts

Corrections:

Correction: Genetically enhanced T lymphocytes and the intensive care unit